SCHEDULE: Amundi Discloses Sanofi Stake Update

Amundi and Amundi Asset Management have updated their Schedule 13G filing regarding their beneficial ownership of Sanofi common stock.

Summary

• Amundi and Amundi Asset Management have filed an amendment to their Schedule 13G, reporting their beneficial ownership of Sanofi securities.
• As of June 30, 2026, Amundi beneficially owns 68,651,904 shares of Sanofi, representing 5.65% of the class.
• Amundi has shared voting power over 36,655,093 shares and shared dispositive power over 68,651,904 shares.
• Amundi does not possess sole voting power or sole dispositive power over any Sanofi shares.
• A significant portion of shares (28,906,920) are held via a French employee shareholding vehicle (FCPE), where Amundi does not exercise voting rights.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It's a routine disclosure of beneficial ownership without new strategic information or significant changes in control, reflecting standard institutional investment practices.

Positives

• Amundi maintains a substantial beneficial ownership stake in Sanofi, indicating continued investment interest.
• The filing clarifies the structure of ownership, particularly regarding shares held through an employee shareholding plan, which is a common and accepted practice.

Negatives

• Amundi has no sole voting power or sole dispositive power over the reported Sanofi shares, meaning their direct control is limited.
• The significant portion of shares held in the FCPE means Amundi's influence on voting decisions is indirect and subject to the FCPE's supervisory board.

Risks

• Potential for changes in Amundi's investment strategy or regulatory shifts could impact their holdings in Sanofi.
• The reliance on the FCPE's supervisory board for voting decisions introduces an element of uncertainty regarding the exercise of shareholder rights.

Future Outlook

This filing is an amendment to a Schedule 13G and does not contain forward-looking statements or specific future guidance from Amundi regarding their investment in Sanofi.

Management Comments

• Amundi does not have voting rights on 28,906,920 shares which are held through a FCPE (Fonds Commun de Placement d'Enterprise, an investment vehicle established under French law), solely dedicated to Sanofi group's employees shareholding.
• Employees of Sanofi are granted the right to participate in stock purchase plans in which the shares acquired are exclusively held in this FCPE, created at the request of Sanofi.
• The voting rights associated to these shares are exercised by the supervisory Board of the FCPE, where representatives of the employees have the majority (if any remaining seats of the supervisory board are designated by Sanofi), and not by Amundi.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures for institutional investors crossing certain ownership thresholds. Amundi's filing confirms its significant, albeit indirectly controlled, stake in Sanofi, a major player in the pharmaceutical industry. This level of ownership is typical for large asset managers.

Comparison to Industry Standards

• Institutional investors like Amundi commonly hold significant stakes in large-cap pharmaceutical companies such as Sanofi.
• The 5.65% ownership is within the typical range for major asset managers holding shares on behalf of clients, often exceeding 5% in large, stable companies.
• The use of FCPEs for employee shareholding plans is a standard practice in many European countries, including France, for companies like Sanofi.

Stakeholder Impact

• Shareholders: The filing confirms Amundi's substantial investment, which can be seen as a sign of confidence in Sanofi's long-term prospects, though Amundi's direct voting influence is limited.
• Employees: The continued operation of the FCPE allows Sanofi employees to participate in share ownership plans, aligning their interests with the company.
• Sanofi Management: The filing provides clarity on a significant institutional shareholder's holdings and the structure of that ownership.

Next Steps

• Amundi will continue to monitor its beneficial ownership of Sanofi shares and file amendments to Schedule 13G as required by SEC regulations.
• The FCPE's supervisory board will continue to exercise voting rights on behalf of Sanofi employees for shares held within the plan.

Key Dates

Keywords

Sanofi, Amundi, Amundi Asset Management, Schedule 13G, Beneficial Ownership, Shareholder, Investment Management, Securities